SF2959
Manufacturers interfering with access to 340B drugs prohibition extension
Legislative Session 94 (2025-2026)
Related bill: HF2703
AI Generated Summary
Purpose of the Bill
The purpose of this bill is to ensure continued access to 340B drugs by extending prohibitions preventing drug manufacturers from interfering with such access. The 340B program is a federal initiative that allows eligible health care providers to purchase outpatient drugs at reduced prices, making them more affordable for patients.
Main Provisions
- The bill aims to repeal the expiration clause of an existing statute, Minnesota Statutes 2024 section 62J.96 subdivision 3, which currently limits the prohibition of manufacturer interference with the 340B drug program.
- By repealing this clause, the bill seeks to make the protection against interference permanent, beyond the current expiration date of July 1, 2027.
Significant Changes
- This legislation removes the expiration date, thereby extending indefinitely the statutory restrictions on drug manufacturers from interfering with healthcare providers' access to discount drugs under the 340B program.
Relevant Terms
340B drugs, drug manufacturers, interference, Minnesota Statutes, repeal, expiration.
Actions
| Date | Chamber | Where | Type | Name | Committee Name |
|---|---|---|---|---|---|
| March 24, 2025 | Senate | Action | Introduction and first reading | ||
| March 24, 2025 | Senate | Action | Referred to | Health and Human Services | |
| March 27, 2025 | Senate | Action | Authors added | ||
| February 17, 2026 | Senate | Action | Author stricken | ||
| Showing the 5 most recent stages. This bill has 4 stages in total. Log in to view all stages | |||||
Citations
You must be logged in to view citations.
Progress through the legislative process
In Committee
Sponsors
You must be logged in to view sponsors.